Una vacuna previene el cáncer de hígado
A vaccine prevents liver cancer
Palabras clave:
hepatitis B, vacuna, cáncer hepatocelular
Resumen
La vacunación contra la hepatitis B sigue siendo la piedra angular de la política de salud pública para prevenir el cáncer hepatocelular y un componente vital de la respuesta global de eliminación de la hepatitis B.
Descargas
La descarga de datos todavía no está disponible.
Citas
Goldstein S, Zhou F, Hadler S, Bell B, Mast E, Margolis H. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005;34(6):1329-1339.
World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017 - Recommendations. Vaccine 2019;37(2):223-225.
Vitaliti G, Praticò AD, Cimino C, Di Dio G, Lionetti E, La Rosa M, Leonardi S. Hepatitis B vaccine in celiac disease: yesterday, today and tomorrow. World J Gastroenterol 2013; 19:838-845
Chan C, Lee S, Lo K. Legend of hepatitis B vaccination: the Taiwan experience. J GastroenterolHepatol 2004;19(2):121-126.
Mast E, Weinbaum C, Fiore A, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults [published correction appears in MMWR Morb Mortal Wkly Rep. MMWR Recomm Rep 2006;55(RR-16):1-CE4.
Lin A, Wong K. Long-term protection of neonatal hepatitis B vaccination in a 30-year cohort in Hong Kong. J Hepatol 2013;59(6):1363-1364.
Geier M, Geier D, Zahalsky A. A review of hepatitis B vaccination. Expert Opin Drug Saf 2003;2(2):113-122.
Greenberg D, Wong V, Partridge S, Howe B, Ward J. Safety and immunogenicity of a combination diphtheria-tetanus toxoids-acellular pertussis-hepatitis B vaccine administered at two, four and six months of age compared with monovalent hepatitis B vaccine administered at birth, one month and six months of age. Pediatr Infect Dis J 2002;21(8):769-777.
Kuan R, Janssen R, Heyward W, Bennett S, Nordyke R. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine. Vaccine 2013;31(37):4024-4032.
Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 2014; 384:2053–63.
Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 2001; 10:751–74.
Levrero M., Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J. Hepatol. 2016;64((Suppl. S1)):S84–S101.
Hyams K.C. Risks of chronicity following acute hepatitis B virus infection: A review. Clin. Infect. Dis. 1995;20:992–1000.
Leroy V., Asselah T. Universal hepatitis B vaccination: The only way to eliminate hepatocellular carcinoma? J. Hepatol.
2015;63:1303–1305.
Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, Hsu HM, Chen HL, Hsu HY, Chen DS. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA. 2000;284(23):3040–42.
Chien YC, Jan CF, Chiang CJ, Kuo HS, You SL, Chen CJ. Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3.8 million vaccinees. Hepatology. 2014;60(1):125–32.
McMahon BJ, Bulkow LR, Singleton RJ, Williams J, Snowball M, Homan C, Parkinson AJ. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology. 2011;54(3):801–07.
Anderson CL, Remschmidt C, Drobnitzky FP, Falkenhorst G, Zimmermann R, Wichmann O, Harder T. Hepatitis B immune status in adolescents vaccinated during infancy: A retrospective cohort study from a pediatric practice in Germany. Hum Vaccin Immunother 2016; 12:779-784.
Young KM, Gray CM, Bekker LG. Is obesity a risk factor for vaccine non-responsiveness? PLoS One 2013; 8(12):e82779
WHO. WHO Global Health Sector Strategy on Viral Hepatitis 2016–2021. WHO; Geneva, Switzerland: 2016.
World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017 - Recommendations. Vaccine 2019;37(2):223-225.
Vitaliti G, Praticò AD, Cimino C, Di Dio G, Lionetti E, La Rosa M, Leonardi S. Hepatitis B vaccine in celiac disease: yesterday, today and tomorrow. World J Gastroenterol 2013; 19:838-845
Chan C, Lee S, Lo K. Legend of hepatitis B vaccination: the Taiwan experience. J GastroenterolHepatol 2004;19(2):121-126.
Mast E, Weinbaum C, Fiore A, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults [published correction appears in MMWR Morb Mortal Wkly Rep. MMWR Recomm Rep 2006;55(RR-16):1-CE4.
Lin A, Wong K. Long-term protection of neonatal hepatitis B vaccination in a 30-year cohort in Hong Kong. J Hepatol 2013;59(6):1363-1364.
Geier M, Geier D, Zahalsky A. A review of hepatitis B vaccination. Expert Opin Drug Saf 2003;2(2):113-122.
Greenberg D, Wong V, Partridge S, Howe B, Ward J. Safety and immunogenicity of a combination diphtheria-tetanus toxoids-acellular pertussis-hepatitis B vaccine administered at two, four and six months of age compared with monovalent hepatitis B vaccine administered at birth, one month and six months of age. Pediatr Infect Dis J 2002;21(8):769-777.
Kuan R, Janssen R, Heyward W, Bennett S, Nordyke R. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine. Vaccine 2013;31(37):4024-4032.
Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 2014; 384:2053–63.
Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 2001; 10:751–74.
Levrero M., Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J. Hepatol. 2016;64((Suppl. S1)):S84–S101.
Hyams K.C. Risks of chronicity following acute hepatitis B virus infection: A review. Clin. Infect. Dis. 1995;20:992–1000.
Leroy V., Asselah T. Universal hepatitis B vaccination: The only way to eliminate hepatocellular carcinoma? J. Hepatol.
2015;63:1303–1305.
Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, Hsu HM, Chen HL, Hsu HY, Chen DS. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA. 2000;284(23):3040–42.
Chien YC, Jan CF, Chiang CJ, Kuo HS, You SL, Chen CJ. Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3.8 million vaccinees. Hepatology. 2014;60(1):125–32.
McMahon BJ, Bulkow LR, Singleton RJ, Williams J, Snowball M, Homan C, Parkinson AJ. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology. 2011;54(3):801–07.
Anderson CL, Remschmidt C, Drobnitzky FP, Falkenhorst G, Zimmermann R, Wichmann O, Harder T. Hepatitis B immune status in adolescents vaccinated during infancy: A retrospective cohort study from a pediatric practice in Germany. Hum Vaccin Immunother 2016; 12:779-784.
Young KM, Gray CM, Bekker LG. Is obesity a risk factor for vaccine non-responsiveness? PLoS One 2013; 8(12):e82779
WHO. WHO Global Health Sector Strategy on Viral Hepatitis 2016–2021. WHO; Geneva, Switzerland: 2016.
Publicado
2022-06-23
Cómo citar
Mengual-Moreno, E., & Lizarzábal-García, M. (2022). Una vacuna previene el cáncer de hígado: A vaccine prevents liver cancer. Revista Profesional HígadoSano, (23), 4-9. https://doi.org/10.5281/zenodo.6708924
Número
Sección
Artículos
